Table 1 Clinical characteristics of 271 HCC patients according to miR-494-3p expression levels.

From: MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN

Feature

miR-494-3p

χ2

p-value

Low (n = 135)

High (n = 136)

All cases

Age, year

  

0.089

0.807

   ≥55

61

59

  

   <55

74

77

  

Gender

  

0.395

0.550

   Male

120

124

  

   Female

15

12

  

AFP, μg/L

  

0.306

0.580

   Positive

60

65

  

   Negative

75

71

  

Cirrhosis

  

0.089

0.802

   Present

84

87

  

   Absent

51

49

  

Tumor size,cm

  

4.605

0.032

   ≥5

70

88

  

   <5

65

48

  

Tumor number

  

4.189

0.041

   Multiple

35

51

  

   Single

100

85

  

Capsule

  

1.354

0.273

   Present

78

69

  

   Absent

57

67

  

Vascular invasion

  

2.016

0.171

   Present

58

47

  

   Absent

77

89

  

TNM stage

  

6.777

0.012

   III–IV

39

60

  

   I-II

96

76

  

BCLC stage

  

1.998

0.179

   C-D

54

66

  

   A-B

81

70

  
  1. #The median expression level was used as the cut-off. Low miR-494-3p expression in each of the 135 patients was defined as a value below the 50th percentile. High miR-494-3p expression in each of the 136 patients was defined as a value above the 50th percentile.
  2. *For analysis of correlation between the expressions levels of miR-494-3p and clinical features, Pearson chi-square tests were used. Results were considered statistically significant at p < 0.05.